NEW DELHI: The Indian Council of Medical Research (ICMR) on Sunday said that a candidate vaccine called ChAdOX1 is being developed by researchers at University of Oxford is the frontrunner in the race to take on the deadly COVID-19 virus which has infected over 23 lakh people globally, killing over 1.60 lakh people.
Dr Raman Gangakhedkar, chief scientist of ICMR, on Sunday said that at least 70 groups of scientists across the world have been working towards a novel coronavirus vaccine and five groups have come into human trial phase — with ChAdOx1 leading the race.
On Friday, scientists at the University of Oxford promised a super-fast vaccine during a virtual press conference, saying it would be available by September. According to lead researcher Professor Sarah Gilbert, their ChAdOx1 vaccine can work against the virus called SARS-CoV-2.
The Oxford vaccine group which was among the first to enter the COVID-19 vaccine race, also promised one million doses of the vaccine by September.
In late March, Professor Gilbert received 2.2 million pounds as funding from the UK government for vaccine development and trials.
Researchers enrolled over 500 healthy volunteers to test if their vaccine can prevent COVID-19.
The vaccine is an adenovirus vaccine vector and was developed at Oxford’s Jenner Institute. Adenoviral vectors are a very well-studied vaccine type, having been used safely in thousands of participants, from 1 week to 90 years of age, in vaccines targeting over 10 different diseases.
“The Oxford team had exceptional experience of a rapid vaccine response, such as to the Ebola outbreak in West Africa in 2014.
This is an even greater challenge. Vaccines are being designed from scratch and progressed at an unprecedented rate,” said Professor Adrian Hill, Director of the Jenner Institute at the University of Oxford.
However, WHO’s latest “Draft landscape of COVID-19 candidate vaccines (April 11 update), lists only three candidate vaccines which are currently in clinical evaluation, and ChAdOx1 is yet to be officially included as the fourth one.
According to the WHO draft, from a total of 70 candidate vaccines in the race, three leading vaccines which are in human testing phase are from CanSino Biological Inc and the Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc; and Moderna Inc along with the National Institute of Allergy and Infectious Diseases (NIAID) in the US.
What probably separates ChAdOx1 — known as recombinant viral vector vaccine — from the rest is the time it promises to take in order to deliver mass quantities.
The irony is: WHO special envoy David Nabarro has warned that there is no guarantee that a coronavirus vaccine can be successfully developed in coming months. (IANS)
